AR and prostate carcinoma: To tackle the mode of action of CuC1 we chose highly aggressive hormone- and docetaxel-refractory PC3-DR cells, as well as 22Rv1 cells, which represent a hormone-refractory AR-V7-positive prostate cancer subtype.